| dc.contributor.author |
Batyodlu, Figen |
|
| dc.contributor.author |
Demirel, Sibel |
|
| dc.contributor.author |
Ozmert, Emin |
|
| dc.contributor.author |
Uzun, Aslihan |
|
| dc.contributor.author |
Yalcindag, Fatime Nilufer |
|
| dc.date.accessioned |
2022-08-17T06:51:21Z |
|
| dc.date.available |
2022-08-17T06:51:21Z |
|
| dc.date.issued |
2017 |
|
| dc.identifier.uri |
http://doi.org/10.3109/09273948.2015.1108445 |
|
| dc.identifier.uri |
https://www.tandfonline.com/doi/full/10.3109/09273948.2015.1108445 |
|
| dc.identifier.uri |
http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2602 |
|
| dc.description.abstract |
Purpose: To evaluate aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration (AMD).
Methods: In total, 81 eyes of 79 patients who underwent intravitreal ranibizumab injection for neovascular AMD were included. Aqueous flare was evaluated before pupillary dilatation with Kowa FM-600 laser flare meter at baseline, and 1 day, and 1 month after intravitreal administration of ranibizumab 0.5 mg (0.05 mL).
Results: The mean anterior chamber flare was 10.7 +/- 6.8 (range: 1.5-35.4) ph/ms before the injection, 12.5 +/- 8.9 (range: 0.3-43) ph/ms on the first day, and 9.9 +/- 5.7 (range: 0.2-28.4) ph/ms in the first month. On the first day, a subtle increasing of flare was observed. However, the difference between the mean aqueous flare levels at baseline and postoperative first day and first month was not statistically different (p>0.05).
Conclusions: No significant short-term intraocular inflammation was noted in these eyes receiving ranibizumab for the treatment of neovascular AMD. |
en_US |
| dc.language.iso |
eng |
en_US |
| dc.publisher |
TAYLOR & FRANCIS INC, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA |
en_US |
| dc.relation.isversionof |
10.3109/09273948.2015.1108445 |
en_US |
| dc.rights |
info:eu-repo/semantics/openAccess |
en_US |
| dc.subject |
Age-related macular degeneration; anterior chamber; aqueous flare; intravitreal injection; ranibizumab |
en_US |
| dc.subject |
INTRAOCULAR INFLAMMATION; BEVACIZUMAB; OUTCOMES; ANCHOR |
en_US |
| dc.title |
Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration |
en_US |
| dc.type |
article |
en_US |
| dc.relation.journal |
OCULAR IMMUNOLOGY AND INFLAMMATION |
en_US |
| dc.contributor.department |
Ordu Üniversitesi |
en_US |
| dc.contributor.authorID |
0000-0002-5787-3879 |
en_US |
| dc.contributor.authorID |
0000-0002-6430-6565 |
en_US |
| dc.identifier.volume |
25 |
en_US |
| dc.identifier.issue |
2 |
en_US |
| dc.identifier.startpage |
229 |
en_US |
| dc.identifier.endpage |
232 |
en_US |